- U.S. health agencies advise pausing Valneva's chikungunya vaccine for ages 60+ due to safety concerns.
- Valneva SE (VALN, Financial) shows a potential upside of 119.75% based on analyst price targets.
- Current brokerage recommendations suggest an "Outperform" status for Valneva SE.
U.S. health agencies, including the CDC and FDA, have recommended a pause on the administration of Valneva’s (VALN) chikungunya vaccine, Ixchiq, for individuals aged 60 and older. This decision arises from safety concerns, with reports of 17 serious adverse events, including two fatalities, among vaccine recipients aged 62-89. The vaccine received approval in November 2023.
Valneva SE (VALN, Financial) is attracting significant attention with its one-year price targets projected by four analysts. The average target price is set at $14.22, presenting a high estimate of $17.93 and a low of $8.07. This forecast suggests a notable upside of 119.75% from the current trading price of $6.47. For investors seeking comprehensive estimate data, please refer to the Valneva SE (VALN) Forecast page.
The consensus from four brokerage firms positions Valneva SE (VALN, Financial) with an average recommendation of 1.8, signaling an "Outperform" rating. In this rating system, 1 represents a Strong Buy, and 5 indicates a Sell, highlighting the favorable outlook for this stock among analysts.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.